Walter A, Rocconi RP, Monk BJ, Herzog TJ, et al. Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in
homologous recombination proficient (HRP) ovarian cancer. Gynecol Oncol 2021 Oct 23. pii: S0090-8258(21)01422.
PMID: 34702567